knowledge -WSS

knowledge

author：fashion 2025-09-30 20:18:47 - browse：5

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： A revolution in caring for preterm infants

WSS

In key trial, Verve's treatment lowers cholesterol levels in patients

STAT Readout: Today's biotech news includes Sana and Amylyx

Female surgeons have lower rates of long

Childhood cancer progress stalls for Black, Hispanic kids: Report

Life sciences deals on track to hit lowest point since 2017

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Wikipedia

knowledge

entertainment

At least 13 dead in Texas as scorching temps continue

PBM reforms clear House panel

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Tori Bowie and the unacceptable rates of Black maternal death

Gain of function research would be limited under House proposal

Dobbs anniversary: the lost opportunity of abortion as health care

Takeaways from AdvaMed, the largest medical devices conference

New air purifier tech could be key to improving indoor air quality

Cancer cells are shown to suck energy source from immune cells

leisure time

How clinical AI models' predictive power can degrade over time

Researchers CRISPR chickens in bid to protect them from bird flu

How doctors and nurses shape Google's AI

European regulators consider appeal over Amylyx ALS drug

Morphosys mixed study results for blood cancer drug

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

leisure time

leisure time

explore

focus